\nRegulatory News:\n<\/p>\n
\nNANOBIOTIX (Paris:NANO) (Euronext: NANO \u2013 ISIN : FR0011341205 \u2013 the \u2018\u2018Company<\/b>\u2019\u2019), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the pricing of its initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,300,000 new ordinary shares (the \u201cNew Shares<\/b>\u201d), consisting of a public offering of 5,445,000 ordinary shares in the form of American Depositary Shares (\u201cADSs<\/b>\u201d), each representing the right to receive one ordinary share, in the United States (the \u201cU.S. Offering<\/b>\u201d) and a concurrent offering of 1,855,000 ordinary shares in certain jurisdictions outside of the United States to certain investors (the \u201cEuropean Offering<\/b>\u201d and together with the U.S. Offering, the \u201cGlobal Offering<\/b>\u201d). The offering price was set at $13.50 per ADS in the U.S. Offering and a corresponding offering price of \u20ac11.14 per New Share based on an exchange rate of \u20ac1.00 = $1.2115 as published by the European Central Bank on December 10, 2020. The aggregate gross proceeds are expected to be approximately $98.6 million, equivalent to approximately \u20ac81.3 million, before deduction of underwriting commissions and estimated expenses payable by the Company. The Global Offering is expected to close on December 15, 2020, subject to the satisfaction of customary closing conditions.\n<\/p>\n
\nAll the securities sold in the Global Offering will be issued by the Company. The ADSs have been approved for listing on the Nasdaq Global Select Market and are expected to begin trading on December 11, 2020 under the ticker symbol \u201cNBTX.\u201d The Company\u2019s ordinary shares are listed on the regulated market of Euronext Paris under the ticker symbol \u201cNANO.\u201d\n<\/p>\n
\nThe New Shares (some of which are represented by ADSs) sold in the Global Offering will be subject to an application for admission to trading on the regulated market of Euronext in Paris (Compartment B) on the same trading line as the existing shares under the same ISIN code FR0011341205 and are expected to be admitted to trading on December 15, 2020.\n<\/p>\n
\nJefferies LLC is acting as global coordinator and joint book-running manager for the Global Offering, and Evercore Group, L.L.C. and UBS Securities LLC are acting as joint book-running managers for the U.S. Offering. Gilbert Dupont is acting as manager for the European Offering (together, the \u201cUnderwriters<\/b>\u201d).\n<\/p>\n
Type of Offering<\/b><\/p>\n
\nThe New Shares will be issued through a capital increase without shareholders\u2019 preferential subscription rights by way of a public offering and under the provisions of Article L.225-136 of the French Commercial Code (Code de commerce<\/i>) and pursuant to the 2nd<\/sup> and 7th<\/sup> resolutions of the Company’s extraordinary general shareholders’ meeting held on November 30, 2020.\n<\/p>\n \nThe offering price per New Share in euros is equal to the volume weighted average price of the Company\u2019s ordinary shares on the regulated market of Euronext in Paris over the last three trading days preceding the start of the offering (i.e., December 7, 8 and 9, 2020), minus a discount of 9.80%, and has been determined by the Company pursuant to the 2nd<\/sup> resolution of the Company’s extraordinary general shareholders’ meeting held on November 30, 2020.\n<\/p>\n Option to Purchase Additional Shares<\/b><\/p>\n \nThe Company has granted the Underwriters an option to purchase (the \u201cUnderwriters\u2019<\/b>Option<\/b>\u201d), for a 30-day period (until January 9, 2021), up to 1,095,000 additional ADSs, which represents 15% of the aggregate amount of the New Shares to be issued in the Global Offering, at the same offering price.\n<\/p>\n Stabilization<\/b><\/p>\n \nIn connection with the Global Offering, Jefferies LLC, acting as stabilization agent, may over-allot the securities or effect transactions with a view to supporting, stabilizing, or maintaining the market price of the securities at a level higher than which might otherwise prevail in the open market. However, there is no assurance that the stabilization agent will take any stabilization action and, if begun, may be ended at any time without prior notice. Any stabilization action or over-allotment shall be carried out in accordance with all applicable rules and regulations and may be undertaken on the regulated market of Euronext in Paris and on the Nasdaq Global Select Market.\n<\/p>\n Dilution<\/b><\/p>\n \nThe 7,300,000 New Shares to be issued in the Global Offering (5,445,000 of which are ordinary shares represented by ADSs) will result in a dilution of approximately 28% of the Company’s outstanding share capital on a non-diluted basis excluding the exercise of the Underwriters\u2019 Option, and approximately 32% of the Company\u2019s outstanding share capital on a non-diluted basis, in the case of a full exercise of the Underwriters\u2019 Option.\n<\/p>\n Estimated Proceeds from the Global Offering<\/b><\/p>\n \nThe gross proceeds of the issuance of the New Shares are expected to be approximately $98.6 million (\u20ac81.3 million), assuming no exercise of the Underwriters\u2019 Option.\n<\/p>\n \nThe Company estimates that the net proceeds of the Global Offering will be approximately $86.7 million (\u20ac71.5 million), after deducting approximately $6.9 million (\u20ac5.7 million) in underwriting commissions and approximately $5.0 million (\u20ac4.1 million) in estimated offering expenses.\n<\/p>\n \nThe Company expects to use the net proceeds from the Global Offering to advance the overall development of NBTXR3, prioritizing the treatment of locally advanced head and neck cancers, as follows (assuming an exchange rate of \u20ac1.00 = $1.2115, the exchange rate on December 10, 2020):\n<\/p>\n \nAs of September 30, 2020, the Company had cash and cash equivalents of \u20ac42.4 million (non audited). The Company believes that the net proceeds from the Global Offering, together with its cash and cash equivalents, will be sufficient to fund its operations through the first quarter of 2023.\n<\/p>\n Underwriting <\/b><\/p>\n \nThe Global Offering is subject to an underwriting agreement entered into on December 10, 2020. The underwriting agreement does not constitute a “garantie de bonne fin<\/i>” within the meaning of Article L. 225-145 of the French Commercial Code (Code de commerce<\/i>).\n<\/p>\n Documentation<\/b><\/p>\n \nThe Company has filed a registration statement, including a prospectus, relating to these securities with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), which was declared effective by the SEC on December 10, 2020. The securities referred to in this press release will be offered only by means of a prospectus in the United States. Copies of the final prospectus relating to and describing the terms of the Global Offering can be obtained, when available, from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com<\/a>; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com<\/a>; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at ol-prospectusrequest@ubs.com<\/a>.\n<\/p>\n \nApplication will be made to list the New Shares on the regulated market of Euronext in Paris pursuant to a listing prospectus subject to an approval from the French Autorit\u00e9 des March\u00e9s Financiers<\/i> (\u201cAMF<\/b>\u201d) and comprising the 2019 Universal Registration Document (Document d\u2019Enregistrement Universel<\/i>) of the Company filed with the AMF on May 12, 2020 under number R.20-010, as completed by a first amendment to such Universal Registration Document filed with the AMF on November 20, 2020 under number D.20-0339-A01 and a second amendment to such Registration Document, which will be filed on December 11, 2020 as well as a Securities Note (Note d\u2019op\u00e9ration<\/i>), including a summary of the prospectus. Following the filing of the second amendment to the 2019 Universal Registration Document, copies of the 2019 Universal Registration Document, as amended, will be available free of charge at the Company\u2019s head office located at 60 rue de Wattignies, 75012 Paris, France, on the Company\u2019s website (www.nanobiotix.com<\/a>) and on the AMF\u2019s website (www.amf-france.org<\/a>).\n<\/p>\n\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20201210006268\/en\/744572\/3\/LOGO_NANO_EXPANDING_LIFE.jpg\"){kind=logo}
<\/td>\n<\/tr>\n